GlassScriptPhysician profile
Amanda Wetzel
NPI 1710489182
$10,992.43
in general payments reported to CMS, 2019-2025
48 companies · $2,782 in 2025
The $2,782 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $907 · 2022: $2,409 · 2023: $2,713 · 2024: $2,182 · 2025: $2,782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,656 · Education: $21.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,656.09 |
| Education | $21.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,272.45 | 2021-2025 | Rybelsus, Ozempic, Tresiba |
| Lilly USA, LLC | $951.85 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Abbott Laboratories | $818.08 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $725.06 | 2021-2025 | Evenity, Repatha, Prolia |
| Corcept Therapeutics | $643.36 | 2021-2025 | Korlym |
| Insulet Corporation | $627.99 | 2021-2025 | Omnipod |
| Dexcom, INC. | $624.43 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $623.68 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $481.39 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Radius Health, INC. | $458.14 | 2022-2025 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $396.96 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.80 | 2022-2025 | Jardiance, Synjardy |
| Tandem Diabetes Care, INC. | $271.27 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $248.11 | 2022-2025 | Minimed 780g, Intellis Adaptivestim |
| Abbvie INC. | $243.51 | 2022-2025 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $238.27 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Mannkind Corporation | $230.58 | 2023 | Afrezza |
| Cequr Corporation | $189.43 | 2024-2025 | Cequr Simplicity |
| Globus Medical, INC. | $172.75 | 2025 | Senza |
| Alexion Pharmaceuticals, INC. | $171.63 | 2023-2025 | Strensiq |
| Recordati_rare_diseases_inc. | $157.59 | 2024-2025 | Isturisa, Signifor Lar |
| Astrazeneca Pharmaceuticals LP | $139.96 | 2021-2022 | |
| Ibsa Pharma INC. | $121.19 | 2022-2025 | Flector, Licart, Tirosint |
| Kyowa Kirin, INC. | $85.04 | 2025 | |
| Sequel Med Tech, LLC | $81.80 | 2025 | Twiist |
| Novartis Pharmaceuticals Corporation | $69.03 | 2024 | |
| Ascendis Pharma Endocrinology INC | $55.25 | 2023-2025 | Yorvipath |
| Merck Sharp & Dohme LLC | $48.03 | 2021-2023 | Belsomra |
| Halozyme INC | $47.50 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.43 | 2022 | |
| Ucb, INC. | $40.78 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.48 | 2021-2023 | Xifaxan |
| Exact Sciences Corporation | $37.21 | 2023 | Cologuard Collection Kit |
| Amneal Pharmaceuticals LLC | $33.87 | 2025 | Unithroid |
| Acella Pharmaceuticals, LLC | $31.69 | 2024-2025 | NP Thyroid 60 |
| Amryt Pharma Holdings LTD | $29.88 | 2023 | Myalept |
| Rhythm Pharmaceuticals, INC. | $29.57 | 2025 | Imcivree |
| Horizon Therapeutics Plc | $28.52 | 2022 | |
| Opko Pharmaceuticals, LLC | $27.25 | 2021 | |
| Beta Bionics, INC. | $24.71 | 2024 | Ilet Bionic Pancreas |
| Madrigal Pharmaceuticals | $24.53 | 2025 | Rezdiffra |
| Vivus LLC | $21.02 | 2024 | Qsymia |
| Daiichi Sankyo INC. | $21.01 | 2021 | |
| Ascensia Diabetes Care US INC. | $20.74 | 2023 | |
| Chiesi USA, INC. | $20.38 | 2025 | Mycapssa |
| Tolmar, INC. | $18.67 | 2025 | Jatenzo |
| Currax Pharmaceuticals LLC | $15.85 | 2025 | Contrave |
| Idorsia Pharmaceuticals US INC | $14.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Wetzel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.